Teva and mAbxience Strengthen Strategic Alliance with New Oncology Biosimilar Candidate Addition Read more
FDA Approves Neoadjuvant Opdivo and Chemotherapy for Resectable Non-Small Cell Lung Cancer Treatment Pathway Read more
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities Read more
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer Read more
FDA Approves Merck’s KEYTRUDA (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) Read more
Amneal and Shilpa Announce FDA Approval of BORUZU, the First Ready-to-Use Version of Bortezomib for subcutaneous administration Read more
European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults Read more
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Read more